Aperio Group’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $19.3M | Buy |
123,557
+3,730
| +3% | +$479K | 0.06% | 322 |
|
|
2020
Q3 | $13.7M | Sell |
119,827
-19,143
| -14% | -$2.07M | 0.05% | 374 |
|
|
2020
Q2 | $15.6M | Buy |
138,970
+41,827
| +43% | +$4.44M | 0.06% | 324 |
|
|
2020
Q1 | $8.72M | Buy |
97,143
+32,956
| +51% | +$3.23M | 0.04% | 457 |
|
|
2019
Q4 | $6.94M | Sell |
64,187
-1,052
| -2% | -$113K | 0.02% | 607 |
|
|
2019
Q3 | $6.39M | Sell |
65,239
-4,325
| -6% | -$488K | 0.03% | 624 |
|
|
2019
Q2 | $9.11M | Sell |
69,564
-4,831
| -6% | -$623K | 0.04% | 501 |
|
|
2019
Q1 | $10.1M | Buy |
74,395
+4,911
| +7% | +$611K | 0.04% | 460 |
|
|
2018
Q4 | $6.76M | Sell |
69,484
-4,123
| -6% | -$487K | 0.03% | 529 |
|
|
2018
Q3 | $10.2M | Sell |
73,607
-14,828
| -17% | -$1.86M | 0.05% | 434 |
|
|
2018
Q2 | $11M | Buy |
88,435
+16,513
| +23% | +$1.93M | 0.05% | 400 |
|
|
2018
Q1 | $8.02M | Buy |
71,922
+8,740
| +14% | +$1.04M | 0.04% | 504 |
|
|
2017
Q4 | $7.56M | Sell |
63,182
-8,446
| -12% | -$1.03M | 0.04% | 502 |
|
|
2017
Q3 | $10M | Buy |
71,628
+12,109
| +20% | +$1.65M | 0.06% | 391 |
|
|
2017
Q2 | $7.24M | Sell |
59,519
-15,912
| -21% | -$1.85M | 0.04% | 466 |
|
|
2017
Q1 | $9.14M | Buy |
75,431
+676
| +0.9% | +$87.2K | 0.06% | 361 |
|
|
2016
Q4 | $9.15M | Buy |
74,755
+17,244
| +30% | +$2.11M | 0.07% | 326 |
|
|
2016
Q3 | $7.05M | Sell |
57,511
-12,679
| -18% | -$1.63M | 0.05% | 431 |
|
|
2016
Q2 | $8.2M | Buy |
70,190
+7,569
| +12% | +$1.07M | 0.06% | 345 |
|
|
2016
Q1 | $8.72M | Sell |
62,621
-6,023
| -9% | -$884K | 0.07% | 306 |
|
|
2015
Q4 | $13.1M | Buy |
68,644
+12,668
| +23% | +$2.21M | 0.12% | 195 |
|
|
2015
Q3 | $8.75M | Buy |
55,976
+3,576
| +7% | +$652K | 0.09% | 274 |
|
|
2015
Q2 | $9.47M | Buy |
52,400
+4,164
| +9% | +$719K | 0.1% | 250 |
|
|
2015
Q1 | $8.36M | Buy |
48,236
+2,435
| +5% | +$441K | 0.09% | 263 |
|
|
2014
Q4 | $8.47M | Buy |
45,801
+2,981
| +7% | +$552K | 0.1% | 233 |
|
|
2014
Q3 | $7.1M | Buy |
42,820
+2,173
| +5% | +$357K | 0.1% | 263 |
|
|
2014
Q2 | $6.35M | Buy |
40,647
+2,783
| +7% | +$439K | 0.09% | 272 |
|
|
2014
Q1 | $5.76M | Buy |
+37,864
| New | +$6.02M | 0.08% | 313 |
|
|
2013
Q4 | – | Sell |
-28,456
| Closed | -$3.41M | – | 371 |
|
|
2013
Q3 | $3.31M | Buy |
28,456
+5,400
| +23% | +$592K | 0.06% | 401 |
|
|
2013
Q2 | $2.13M | Buy |
+23,056
| New | +$2.22M | 0.05% | 477 |
|
Other funds holding ALXN
BBA
Aperio Group's ALXN Position: Q4 2020 in Review
Aperio Group increased its Alexion Pharmaceuticals (ALXN) stake by 3.1% in Q4 2020, buying an estimated $479K and bringing the position to 123,557 shares worth $19.3M. The position accounts for 0.06% of the portfolio, ranked #322.
Aperio Group first reported a position in ALXN in Q2 2013 and has held it in 30 quarters since. 825 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.
- Aperio Group held 123,557 shares of Alexion Pharmaceuticals worth $19.3M as of Q4 2020.
- Aperio Group bought 3,730 Alexion Pharmaceuticals shares in Q4 2020, an estimated $479K.
- Alexion Pharmaceuticals made up 0.06% of Aperio Group's portfolio in Q4 2020, its #322 holding.
- Aperio Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 30 quarters since.
- 825 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.